Barclays lowered the firm’s price target on RenaissanceRe (RNR) to $231 from $234 and keeps an Underweight rating on the shares as part of a Q1 earnings preview for the insurance group. With life earnings facing challenges Barclays favors group benefits, excess capital, and “cheap” cash flows, the analyst tells investors in a research note. The firm says the sector is “navigating uncertainty.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNR:
- RenaissanceRe price target lowered to $235 from $245 at Morgan Stanley
- RenaissanceRe price target lowered to $271 from $277 at Wells Fargo
- RenaissanceRe price target lowered to $279 from $294 at Citizens JMP
- RenaissanceRe upgraded to Overweight from Neutral at JPMorgan
- RenaissanceRe price target lowered to $426 from $437 at BofA
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue